Dr. Reddy’s intends to acquire OctoPlus

22 Oct 2012 Evaluate

Dr. Reddy’s Laboratories (Dr. Reddy’s), together with its subsidiaries, has announced its intention to acquire the issued and outstanding shares of OctoPlus N.V. (OctoPlus), a service based specialty pharmaceutical company, through a public offer, for an offer price of euro 27.39 million cum dividend in cash, representing 100% of the issued and outstanding ordinary shares.

The offer price represents a premium of 30% over the closing price of OctoPlus as of the end of the day October 19, 2012. Besides, this deal will help expand the expertise and scientific capabilities of Dr. Reddy’s.

The pharma company currently holds an irrevocable commitment from shareholders representing over 50% of OctoPlus’s issued and outstanding shares. Further, the executive board and the supervisory board of OctoPlus have unanimously recommended the offer to the remaining shareholders.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1267.15 -7.90 (-0.62%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×